Source comparison
CJC-1295 no DAC 30s Age Protocol: Dosing Comparison
20s (baseline GH high) 75–100 mcg 3x/week 60–90 min pre-sleep 8 weeks Lower dose amplifies already-strong endogenous pulses; shorter cycles prevent receptor saturation 30s (moderate GH decline) 100–150 mcg 8–12 weeks Standard therapeutic range for pulse amplit
This comparison does not assign a generated winner or score.
- 20s (baseline GH high)
- 75–100 mcg
- 3x/week
- 60–90 min pre-sleep
- 8 weeks
- Lower dose amplifies already-strong endogenous pulses; shorter cycles prevent receptor saturation
- 30s (moderate GH decline)
- 100–150 mcg
- 8–12 weeks
- Standard therapeutic range for pulse amplitude restoration without overriding natural rhythm
- 40s (accelerated decline)
- 150–200 mcg
- 3–4x/week
- 12 weeks
- Higher dose compensates for reduced receptor density; extended cycle addresses sustained GH deficit
- 50s+ (significant decline)
- 200 mcg + GHRP stack
- 4–5x/week
- 60–90 min pre-sleep + AM dose
- 12–16 weeks
- Dual-pathway stimulation (GHRH + GHRP) required to overcome somatostatin dominance and receptor loss
- Professional Assessment
- Dose individualisation based on IGF-1 response at week 4 is more predictive of outcomes than age-based dosing alone. Bloodwork-driven titration prevents both underdosing (no measurable benefit) and overdosing (metabolic side effects without additional GH elevation)